‘Third member of FDA expert committee resigns over controversial Alzheimer’s therapy decision’ -State News Report
https://www.statnews.com/2021/06/10/third-member-of-fda-expert-committee-resigns-over-controversial-alzheimers-therapy-decision/
With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch
Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm.
UBS Upgrades Biogen to Buy, Announces $463 Price Target
UBS analyst Colin Bristow upgrades Biogen (NASDAQ:BIIB) from Neutral to Buy and announces $463 price target.
Why Biogen Shares Are Trading Higher Today
Biogen Inc (NASDAQ: BIIB) shares are trading higher by 3.2% at $419.81 after SVB Leerink maintained an Outperform on the stock and raised its price target from $380 to $475.
‘SPACs Attack’ Recap: Looking Back At 3 SPAC Deals, SPAC Rumors And The Latest SPAC Headlines And Earnings
Last week featured three announced SPAC deals. The week also had earnings from several well-known former SPACs. Here is a look back at the week that was SPACs for deals, rumors and headline news all covered on Benzinga’s “SPACs Attack.”
Where Biogen Stands With Analysts
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago
Oppenheimer Maintains Outperform on Biogen, Raises Price Target to $325
Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $300 to $325.
Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
Biogen Inc. (NASDAQ:BIIB) and Envisagenics today announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases. As part of the
Unusual Options Activity Insight: Biogen
On Monday, shares of Biogen (NASDAQ:BIIB) saw unusual options activity. After the option alert, the stock price moved up to $275.74.
Denali-Biogen Parkinson’s Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End
Denali Therapeutics Inc (NASDAQ: DNLI) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The drug…